The Pro Medicus Ltd (ASX: PME) share price is in focus today after the company announced a significant seven-year, A$24 million contract win with Billings Clinic – Logan Health in the United States.

What did Pro Medicus report?

• Secured a 7-year, A$24 million deal with Billings Clinic – Logan Health
• Contract covers deployment of Visage 7 Viewer, Workflow, and Open Archive solutions
• Cloud-based implementation planned, supporting digital transformation for the client
• Migrating legacy image archives to the Visage 7 Open Archive platform
• Agreement operates on a transaction-based model, with potential for further upside

What else do investors need to know?

Billings Clinic – Logan Health is a leading not-for-profit healthcare provider across Montana and the surrounding region, operating 25 hospitals and over 1,000 beds. This contract reflects Pro Medicus’s strong reputation for delivering scalable and innovative cloud-based imaging solutions.

The implementation will see Visage 7’s entire platform integrated, including image distribution within the client’s electronic health record system. Rollout planning is underway, aiming for a go-live date in early 2027.

What did Pro Medicus management say?

Pro Medicus CEO Dr Sam Hupert said:

Billings Clinic – Logan Health provides comprehensive community-focused care to patients across a broad, multi-state, rural area. They join an ever-growing list of Visage 7 clients to opt for our fully cloud-based platform, which, as a result of our CloudPACS strategy, is becoming the standard in the North American healthcare IT market.

What’s next for Pro Medicus?

Pro Medicus will begin planning for the rollout with its proven cloud-based implementation processes. The company continues to report strong interest in its solutions, with management pointing to a robust North American sales pipeline spanning all market segments.

This deal supports Pro Medicus’s broader strategy of expanding its North American footprint and reinforces its position as a leading healthcare imaging provider with widespread cloud adoption.

Pro Medicus share price snapshot

Over the past 12 months, Pro Medicus shares have declined 39%, trailing the S&P/ASX 200 Index (ASX: XJO), which has declined 2% over the same period.

View Original Announcement

The post Pro Medicus signs A$24M US deal appeared first on The Motley Fool Australia.

More reading

• ASX 200 utilities and healthcare shares win the week again
• These are the best 3 ASX growth shares I own and I’d buy more of today
• Down 44%: Will you regret not buying Pro Medicus shares?
• Droneshield vs Pro Medicus: Which is the better ASX growth stock right now?
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Certain ASX blue-chip shares are excellent contenders for passive income given their pleasing dividend yields.

Strength and stability are reassuring factors for investors seeking a strong dividend each year, even through tougher economic conditions.

With that in mind, I want to highlight the two stocks below as contenders for passive income.

Charter Hall Long WALE REIT (ASX: CLW)

Rental income is predictable and locked in thanks to the terms of lease agreements. This makes certain real estate investment trusts (REITs) very attractive.

Charter Hall Long WALE REIT has a diversified portfolio of properties. Within that portfolio are long-term leases.

It has a weighted average lease expiry (WALE) of around nine years, which is a long time and provides significant rental security.

The REIT has an occupancy rate of around 100%. Approximately 99% of the portfolio is leased to blue-chip tenants such as government entities, Endeavour Group Ltd (ASX: EDV), Telstra Group Ltd (ASX: TLS), BP, Coles Group Ltd (ASX: COL), Metcash Ltd (ASX: MTS), David Jones, Westpac Banking Corp (ASX: WBC), Arnott’s Group and Sonic Healthcare Ltd (ASX: SHL).

It’s those sorts of tenants that can provide investors with commendable reliability during all economic conditions.

I like the areas of the commercial market the REIT is invested in, including hotels, grocery and distribution, telecommunications exchanges, data centres, service stations food manufacturing, healthcare and more.

Despite the headwind of higher interest rates, the ASX blue-chip share is expected to maintain its operating earnings per security (EPS) of 25.5 cents in FY27. The business plans to pay a 100% distribution payout ratio, so the distribution is also expected to be 25.5 cents per security.

The likely payout for the 2027 financial year translates into a forward distribution yield of 7.8%.

Australian United Investment Company Ltd (ASX: AUI)

Another ASX blue-chip share that looks compelling is this listed investment company (LIC) with a long history of paying dividends.

It was founded in 1953 and it invests in both ASX shares and international shares. It aims to provide sustainable dividend income over the long-term.

At the end of September 2026, its largest holdings were Commonwealth Bank of Australia (ASX: CBA), BHP Group Ltd (ASX: BHP), Rio Tinto Ltd (ASX: RIO), CSL Ltd (ASX: CSL), ANZ Group Holdings Ltd (ASX: ANZ), Wesfarmers Ltd (ASX: WES), Westpac Banking Corp (ASX: WBC), Washington H. Soul Pattinson and Co. Ltd (ASX: SOL) and Transurban Group (ASX: TCL).

The LIC has an incredibly low management expense ratio of 0.09% which is one of the lowest-costing portfolios in Australia.

The ASX blue-chip share has paid a dividend every year since its listing in 1974 and has maintained or increased its dividend each year since 1994.

In FY27, it plans to pay 37 cents per share of ordinary dividends and a special dividend of 8 cents per share. The total dividend per share of 45 cents translates into a grossed-up dividend yield of 5.4%, including franking credits, at the time of writing.

It currently trades at a 14% discount to the net tangible asset (NTA) per share, as of September 2026. This discount makes the valuation look attractive to me.

The post 2 ASX blue-chip shares offering large dividend yields appeared first on The Motley Fool Australia.

More reading

• Dividend yields in focus as seven ASX real estate companies hit 12-month lows
• How much is needed in superannuation to target a $7,500 monthly passive income?
• How much passive income can I earn off a $700,000 superannuation balance?
• How much is needed in superannuation to target a $100,000 annual passive income?
• 2 ASX passive income share ideas I’d use to generate $600 a month in 2027

Motley Fool contributor Tristan Harrison has positions in Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Transurban Group, Washington H. Soul Pattinson and Company Limited, and Wesfarmers. The Motley Fool Australia has positions in and has recommended Telstra Group, Transurban Group, and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia has recommended BHP Group, CSL, Sonic Healthcare, and Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

If you are in the market for some new portfolio additions, it could be worth seeing what the team at Bell Potter is saying about the three ASX shares in this article. 

Does the broker rate them as buys, holds, or sells? Let’s find out:

Mesoblast Ltd (ASX: MSB)

Bell Potter notes that this biotechnology company released its quarterly update and revealed Ryoncil sales of US$28 million, which was well short of its forecast of US$40 million.

However, it points out that revenues were adversely impacted by low patient numbers across the summer months, with the low point in August.

As a result, the broker remains positive and has retained its buy rating on Mesoblast shares with a slightly trimmed price target of $4.40. It said:

The miss on September quarter revenues requires a downgrade to the forecast for FY27 Ryoncil revenues. The forecast is lowered by 18% ($243m to $203m) with the NPAT reduced by a similar quantum to $26.7m. The FY28 revenue forecast is reduced by 7%, however, there are no changes to the long-term outlook. Price target is reduced to $4.40.

PLS Group Ltd (ASX: PLS)

Bell Potter has also been looking at lithium giant PLS Group. It highlights that the company has announced plans to double Pilgangoora nameplate spodumene concentrate capacity to 2Mtpa. 

A feasibility study outlined development capex of $1.9 billion, with an incremental net present value (8% discount rate) of $2.7 billion.

In response, the broker has retained its buy rating on PLS shares with a trimmed price target of $4.10. It said:

While P2000 introduces medium-term execution risk, completion will meaningfully strengthen PLS’ long-term position as a large, low-cost hard-rock lithium producer. The company retains offtake optionality with ~50% of FY30 expected SC production of 2Mtpa uncontracted. Colina development studies are progressing, providing additional organic growth optionality in markets with strong underlying demand fundamentals from EV adoption and BESS deployment.

Seek Ltd (ASX: SEK)

The broker isn’t quite as positive on this job listings company’s shares. 

However, it was pleased to see that Seek’s job ad volume index slowed its annual rate of decline to -3.5% in September (Aug -5.3%). It also printed a third consecutive non-negative month on month number.

In response to the news, the broker has retained its hold rating on Seek shares with an improved price target of $13.60. It said:

We await a positive shift in sentiment or further visibility on jobs volumes recovery; potential near term Growth Fund monetisation remains an asymmetric upside risk, though the current interest rate backdrop may also be an additional headwind in seeking a desired exit price for nominated assets. 

SEK appears to be improving operations to sustainably target 10% yield growth on top of strong cost controls, however, despite trading at deep value ex. Growth Fund, macro-based headwinds suggest difficult sentiment near-term for the stock. Maintain Hold.

The post Buy, hold, sell: Mesoblast, PLS, and SEEK shares appeared first on The Motley Fool Australia.

More reading

• These are the 10 most shorted ASX shares
• 5 things to watch on the ASX 200 on Monday
• Top brokers name 3 ASX shares to buy next week
• 3 ASX 200 mining shares to buy with 41% to 79% upside ahead: broker
• 9 ASX 200 shares experts are backing for growth amid market weakness

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.